DexCom (DXCM) Revenue — Quarter Ended Dec 31, 2023
Revenue for the quarter increased compared to the prior quarter and rose substantially compared to the same quarter a year ago. The annual trend shows consistent quarterly growth throughout the fiscal year.
Key takeaway
Quarter ended Dec 31, 2023 · FY2023 Q4
Revenue for the quarter increased compared to the prior quarter and rose substantially compared to the same quarter a year ago. The annual trend shows consistent quarterly growth throughout the fiscal year.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$1B
Revenue reported for this quarter.
Quarter-over-quarter
+6.1%
Change from the immediately preceding quarter.
Year-over-year
+26.9%
Change from the comparable year-ago quarter.
Trailing four quarters
$3.6B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Mar 31, 2023 | $741.5M | +17.9% |
| Jun 30, 2023 | $871.3M | +25.2% |
| Sep 30, 2023 | $975M | +26.7% |
| Dec 31, 2023 | $1B | +26.9% |
Revenue performance
Reported revenue for the quarter was higher than the immediately preceding quarter, reflecting continued sequential growth.
Quarterly comparison
Compared to the same quarter one year earlier, revenue increased substantially, with the year-over-year growth rate consistent with the prior two quarters.
What to watch
The filing context discusses factors that may affect future capital requirements, including international expansion and operational scaling.